IP Verse

Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer

Patent No. EP3791896 (titled "Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer") was filed by Astellas Pharma on May 21, 2013. The application was issued on Jan 10, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DR H ULRICH DORRIESOct 10, 2024DORRIES
DR H ULRICH DORRIESOct 10, 2024DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN
DR STRAUSOct 10, 2024STRAUS
MAIWALDOct 8, 2024MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3791896

ASTELLAS PHARMA
Application Number
EP20194625A
Filing Date
May 21, 2013
Status
Revoked
May 23, 2025
Publication Date
Jan 10, 2024
External Links
Slate, Register , Google Patents